- Home
- GYRE vs MTAL Comparison
GYRE vs MTAL Comparison
Compare GYRE & MTAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GYRE
- MTAL
- Stock Information
- Founded
- GYRE 2002
- MTAL 2021
- Country
- GYRE United States
- MTAL Jersey
- Employees
- GYRE N/A
- MTAL N/A
- Industry
- GYRE Biotechnology: Pharmaceutical Preparations
- MTAL Blank Checks
- Sector
- GYRE Health Care
- MTAL Finance
- Exchange
- GYRE Nasdaq
- MTAL Nasdaq
- Market Cap
- GYRE 897.1M
- MTAL 994.8M
- IPO Year
- GYRE N/A
- MTAL 2021
- Fundamental
- Price
- GYRE $8.21
- MTAL $12.13
- Analyst Decision
- GYRE
- MTAL Hold
- Analyst Count
- GYRE 0
- MTAL 4
- Target Price
- GYRE N/A
- MTAL $12.08
- AVG Volume (30 Days)
- GYRE 80.3K
- MTAL 761.4K
- Earning Date
- GYRE 08-11-2025
- MTAL 07-23-2025
- Dividend Yield
- GYRE N/A
- MTAL N/A
- EPS Growth
- GYRE N/A
- MTAL N/A
- EPS
- GYRE 0.02
- MTAL N/A
- Revenue
- GYRE $102,189,000.00
- MTAL $340,736,000.00
- Revenue This Year
- GYRE $21.04
- MTAL $17.39
- Revenue Next Year
- GYRE $89.64
- MTAL $24.69
- P/E Ratio
- GYRE $170.09
- MTAL N/A
- Revenue Growth
- GYRE N/A
- MTAL 114.30
- 52 Week Low
- GYRE $6.11
- MTAL $7.69
- 52 Week High
- GYRE $19.00
- MTAL $14.31
- Technical
- Relative Strength Index (RSI)
- GYRE 60.94
- MTAL 62.12
- Support Level
- GYRE $6.62
- MTAL $12.02
- Resistance Level
- GYRE $7.47
- MTAL $12.12
- Average True Range (ATR)
- GYRE 0.46
- MTAL 0.04
- MACD
- GYRE 0.12
- MTAL -0.01
- Stochastic Oscillator
- GYRE 99.09
- MTAL 95.65
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.